Who owns Liminatus Pharma, Inc. (LIMN)? Elite investor 13F holders
2 tracked elite investors reported holding Liminatus Pharma, Inc as of 2026-06-30, including Saba Capital, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Saba Capital | LIMINATUS PHARMA INC. | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 11910.00 USD | 233761.000000 | Shares | hold | Original filing |
| D.E. Shaw | LIMINATUS PHARMA INC. | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2934.00 USD | 83353.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.